<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28780" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Scleritis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lagina</surname>
            <given-names>Amy</given-names>
          </name>
          <aff>University of Michigan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramphul</surname>
            <given-names>Kamleshun</given-names>
          </name>
          <aff>Shanghai Jiao Tong University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amy Lagina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamleshun Ramphul declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28780.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Scleritis is a severe ocular inflammatory condition affecting the outer covering of the eye. Scleritis has a high association with systemic disease. This activity reviews the evaluation and treatment of scleritis and highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the types of scleritis.</p></list-item><list-item><p>Explain the cause of scleritis.</p></list-item><list-item><p>Articulate the proper treatment protocols for each type of scleritis.</p></list-item><list-item><p>Employ interprofessional team strategies for improving care coordination and communication in the management of scleritis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28780&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28780">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28780.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Scleritis is a severe ocular inflammatory condition affecting the sclera, the&#x000a0;outer covering of the eye. It can&#x000a0;be categorized as anterior with diffuse, nodular, or necrotizing subtypes and posterior with diffuse or nodular subtypes. Scleritis can be visually significant, depending on the severity and presentation and any associated systemic conditions.<xref ref-type="bibr" rid="article-28780.r1">[1]</xref> The presentation can be unilateral or bilateral.&#x000a0;</p>
      </sec>
      <sec id="article-28780.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Scleritis can be idiopathic or caused by infectious or noninfectious conditions. Additionally, associations with malignancy, autoimmune diseases, and surgically induced or medication side effects are causative factors. Viruses, bacteria, fungi, and parasites can cause infectious scleritis and are reported to occur in 4% to 10% of all cases.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref> Choroidal melanomas and conjunctival tumors can create ocular inflammation that can mimic the signs and symptoms of scleritis. 50% of patients with scleritis will have an autoimmune condition, sometimes undiagnosed at the time of presentation. Rheumatoid arthritis and systemic vasculitic conditions are most commonly associated with scleritis.&#x000a0;<xref ref-type="bibr" rid="article-28780.r3">[3]</xref></p>
        <p>Surgically induced scleritis has been associated with pterygium removal and scleral buckle procedures. Medications used to treat osteoporosis such as bisphosphonates&#x000a0;have been found to cause scleritis; however, reports of this occurrence are rare.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref></p>
      </sec>
      <sec id="article-28780.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Limited, population-based studies have reported 10,500 cases of scleritis in the United States per year or an estimated four to six cases per 100,000 persons.<xref ref-type="bibr" rid="article-28780.r3">[3]</xref></p>
        <p>It affects patients in middle age, commonly between 47 to 60 years.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref> Scleritis is more common in women, with a 60% to 74% predominance.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref>&#x000a0;Limited information is known about the incidence of children besides case reports.</p>
      </sec>
      <sec id="article-28780.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathophysiology of scleritis is still under investigation. The anatomical structure of the sclera includes an extracellular matrix of collagen, elastin, and proteoglycans that closely resemble the components of joints, causing it to be susceptible to inflammatory conditions such as rheumatoid arthritis.<xref ref-type="bibr" rid="article-28780.r1">[1]</xref> Additionally, the sclera is mostly avascular and requires the transport of nutrients and the removal of cellular wastes on the surrounding episcleral and choroidal vascular systems.</p>
      </sec>
      <sec id="article-28780.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The disease's histopathological features are similar to those&#x000a0;seen in vasculitic conditions. Scleral biopsies from patients with severe scleritis or necrotizing scleritis demonstrated vascular occlusions and infiltration, necrosis, and evidence of macrophages and T cells.<xref ref-type="bibr" rid="article-28780.r3">[3]</xref></p>
      </sec>
      <sec id="article-28780.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation can vary depending on the location and subtype of scleritis and can be unilateral or bilateral.<xref ref-type="bibr" rid="article-28780.r4">[4]</xref>&#x000a0;<xref ref-type="bibr" rid="article-28780.r5">[5]</xref></p>
        <p>
<bold>Anterior</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anterior from the rectus muscle's limbus-insertion</p>
          </list-item>
          <list-item>
            <p>Occurs in 98% of cases</p>
          </list-item>
          <list-item>
            <p>Mild to moderate pain and tenderness; worse at night</p>
          </list-item>
          <list-item>
            <p>Pain with eye movement</p>
          </list-item>
          <list-item>
            <p>A blue-violet hue of deep vessels; best seen in daylight or natural illumination</p>
          </list-item>
          <list-item>
            <p>Photophobia, tearing, and possibly decreased vision</p>
          </list-item>
          <list-item>
            <p>No vessel blanching with the installation of 2.5% topical phenylephrine</p>
          </list-item>
        </list>
        <p>
<bold>Diffuse</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Most common (45% to 61%)</p>
          </list-item>
          <list-item>
            <p>Extensive scleral edema; congestion of deep and superficial vessels</p>
          </list-item>
          <list-item>
            <p>Can be localized or encompass the entire anterior sclera</p>
          </list-item>
        </list>
        <p>
<bold>Nodular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple, well-defined, and non-moveable nodules</p>
          </list-item>
          <list-item>
            <p>Scleral edema and congestion of vessels</p>
          </list-item>
          <list-item>
            <p>Usually more localized</p>
          </list-item>
        </list>
        <p>
<bold>Necrotizing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>With inflammation &#x02013; intense congestion of vessels</p>
          </list-item>
          <list-item>
            <p>Severe pain</p>
          </list-item>
          <list-item>
            <p>Most severe form with the worst prognosis</p>
          </list-item>
          <list-item>
            <p>Highest association with a systemic disease</p>
          </list-item>
          <list-item>
            <p>Scleral thinning and exposure of choroid possible</p>
          </list-item>
          <list-item>
            <p>Inflammation can spread to other ocular tissues such as the cornea, ciliary body, or trabecular meshwork</p>
          </list-item>
        </list>
        <p>
<bold>Necrotizing&#x000a0;Without inflammation (Scleromalacia perforans)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe scleral thinning- with visible choroid</p>
          </list-item>
          <list-item>
            <p>Can be asymptomatic or can have reduced acuity resulting from corneal astigmatism caused by the scleral thinning&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Posterior</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Behind the insertion of the rectus muscles</p>
          </list-item>
          <list-item>
            <p>Occurs in 2% of cases</p>
          </list-item>
          <list-item>
            <p>Can occur in conjunction with anterior scleritis&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>May present with decreased vision, with or without ocular pain</p>
          </list-item>
          <list-item>
            <p>Retinal detachments, optic nerve swelling, and cotton wools spots can be seen on dilated examination</p>
          </list-item>
          <list-item>
            <p>Diffuse or nodular subtypes can be differentiated with B-scan, CT), or MRI</p>
          </list-item>
          <list-item>
            <p>B-scan ultrasound displays thickening of the posterior sclera (greater than 2millimeters); retrobulbar thickening and fluid surrounding the optic nerve create a characteristic &#x0201c;T&#x0201d; sign</p>
          </list-item>
          <list-item>
            <p>Diffuse - Diffuse thickening of sclera and choroid</p>
          </list-item>
          <list-item>
            <p>Nodular- Scleral nodules seen on B-scan</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28780.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis is based on the clinical presentation and ocular exam with a detailed history and review of systems, targeted laboratory tests, and imaging studies.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref></p>
        <p>
<bold>Common Lab Tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antineutrophil cytoplasmic antibodies (ANCAs) &#x02013; specific for granulomatosis with polyangiitis (Wegener granulomatosis)</p>
          </list-item>
          <list-item>
            <p>Antinuclear Antibodies (ANA) &#x02013; suggestive of systemic lupus erythematosus and other autoimmune conditions&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Complete blood count(CBC) with differential &#x02013; identify infectious or inflammatory processes</p>
          </list-item>
          <list-item>
            <p>C-reactive protein &#x02013; elevated in inflammatory conditions</p>
          </list-item>
          <list-item>
            <p>ESR &#x02013; suggestive of giant cell arteritis, inflammatory or infectious processes</p>
          </list-item>
          <list-item>
            <p>HLA-B27 - &#x000a0;more useful in cases of uveitis; rare association with scleritis</p>
          </list-item>
          <list-item>
            <p>Lyme serology &#x02013; rule out Lyme Disease, presents with recurrent diffuse anterior scleritis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid factor &#x02013; suspect for rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Angiotensin-converting enzyme (ACE) - &#x000a0;suggestive of sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Serum lysozyme &#x02013; suggestive of sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Rapid plasma reagin (RPR) &#x02013; suggestive for syphilis</p>
          </list-item>
          <list-item>
            <p>Fluorescent treponemal antibody absorption test (FTA-ABS) &#x02013; suggestive for syphilis&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Imaging</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest X-Ray &#x02013; rule out sarcoidosis</p>
          </list-item>
          <list-item>
            <p>B-scan &#x02013; assess for posterior scleritis</p>
          </list-item>
          <list-item>
            <p>MRI &#x02013; can be used if B-scan is non-conclusive</p>
          </list-item>
          <list-item>
            <p>CT &#x02013; can be used if MRI is non-indicated (posterior scleritis)</p>
          </list-item>
          <list-item>
            <p>Ultrasound biomicroscopy (UBM) &#x02013; can be used to differentiate episcleritis from scleritis</p>
          </list-item>
          <list-item>
            <p>Optical coherence tomography (OCT) &#x02013; can display thickened sclera on anterior segment OCT and thickened choroidal tissue</p>
          </list-item>
          <list-item>
            <p>Anterior segment fluorescein and indocyanine green angiography (ICGA) &#x02013; useful in visualizing necrosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28780.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment and management of scleritis are designed to determine any causative factor, manage ocular inflammation, control ocular pain and symptoms, prevent sequela, and reduce recurrences.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref><xref ref-type="bibr" rid="article-28780.r4">[4]</xref>&#x000a0;<xref ref-type="bibr" rid="article-28780.r5">[5]</xref></p>
        <p>
<bold>Anterior Infectious</bold>
</p>
        <p>Treatment tailored to the infectious cause</p>
        <p>
<bold>Anterior Noninfectious</bold>
</p>
        <p>
<bold>
<italic toggle="yes">First-line treatments</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Topical corticosteroid eyedrops
<list list-type="bullet"><list-item><p>Can be used in mild cases; some report very limited success</p></list-item><list-item><p>Prednisolone acetate 1.0% or difluprednate 0.05% four times per day are options</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Oral NSAIDs
<list list-type="bullet"><list-item><p>Can start with one agent and switch to another agent if not effective</p></list-item><list-item><p>Indomethacin, commonly used, 50 mg, 3 times per day</p></list-item><list-item><p>Ibuprofen 600 mg, 3 times per day</p></list-item><list-item><p>Naproxen 500 mg, 2 times per day&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Second-line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral corticosteroids
<list list-type="bullet"><list-item><p>Prescribed when oral NSAID treatment fails</p></list-item><list-item><p>Oral prednisone 1 mg/kg/day; 60 to 80 mg per day</p></list-item><list-item><p>Dose continued until one month after the resolution of scleritis, then tapered accordingly</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Subconjunctival corticosteroid injection
<list list-type="bullet"><list-item><p>Can be used when steroids are contraindicated</p></list-item><list-item><p>Controversial use with previous studies of scleral necrosis/perforation</p></list-item><list-item><p>More recent reports have indicated improved safety and efficacy of injections</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>&#x000a0; &#x000a0; Third line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunosuppressive agents (steroid-sparing)
<list list-type="bullet"><list-item><p>Reserved for more severe cases of scleritis, with oral steroid treatment failure or concern for side effects with long-term oral steroid use</p></list-item><list-item><p>Methotrexate is the most commonly prescribed agent; starting dose of 0.15 mg/kg per week in combination with folic acid supplements</p></list-item><list-item><p>Other agents include azathioprine, mycophenolate, and cyclophosphamide</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>&#x000a0; &#x000a0; Fourth line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Biologics
<list list-type="bullet"><list-item><p>Ongoing research with the use of biologics such as infliximab and rituximab has been shown to have a positive treatment response&#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Posterior</bold>&#x000a0;</p>
        <p>Requiring intense and immediate treatment</p>
        <p>
<italic toggle="yes">
<bold>&#x000a0; &#x000a0; First-line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral NSAIDs
<list list-type="bullet"><list-item><p>Commonly used: indomethacin, naproxen, ibuprofen</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>&#x000a0; &#x000a0; Second-line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral corticosteroids</p>
          </list-item>
        </list>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; - Prescribed when oral NSAID treatment fails</p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; - Oral prednisone of 1 mg/kg/day; 60 to 80 mg per day</p>
        <p>
<italic toggle="yes">
<bold>&#x000a0; &#x000a0; Third line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunosuppressive/antimetabolites agents
<list list-type="bullet"><list-item><p>Reserved for severe cases of scleritis and with high dose oral steroid treatment failure after 1 month</p></list-item><list-item><p>Commonly prescribed agents include methotrexate, azathioprine, and mycophenolate&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>&#x000a0; &#x000a0; Fourth line treatments</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Biologics
<list list-type="bullet"><list-item><p>Infliximab and rituximab</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28780.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The main differential diagnosis of scleritis is episcleritis. Episcleritis is defined as inflammation of the superficial episcleral tissues and blood vessels. Patients can present with mild pain, redness, foreign body sensation, and tearing. Upon installation of 2.5% topical phenylephrine in the affected eye, the blood vessels will blanch with episcleritis but will not blanch with scleritis.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref> Episcleritis is usually idiopathic and resolves without treatment.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-28780.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Visual prognosis is relatively good for patients with mild or moderate scleritis that respond well to the appropriate medical treatment and management of any underlying systemic condition.<xref ref-type="bibr" rid="article-28780.r6">[6]</xref>&#x000a0;Necrotizing and posterior scleritis cases pose a higher risk of visual loss to the extent of the inflammation and involvement of other ocular structures.</p>
      </sec>
      <sec id="article-28780.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Sequela resulting from scleritis can vary depending on the severity of presentation and any associated autoimmune conditions and can include decreased vision, cataracts, increased intraocular pressure, scleral thinning or melting, and corneal thinning.&#x000a0;<xref ref-type="bibr" rid="article-28780.r6">[6]</xref></p>
      </sec>
      <sec id="article-28780.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>it is important to discuss the risk of associated systemic conditions with patients with scleritis. Emphasis on proper pain management and control of inflammation is essential for visual recovery and improved prognosis.&#x000a0;</p>
      </sec>
      <sec id="article-28780.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>At least half of scleritis cases can be linked to an autoimmune condition. Order specific laboratory tests and imaging according to patient demographics, detailed history, and physical examination. Investigation for an associated autoimmune condition must be completed at first presentation of scleritis if the patient is unaware of any systemic health problems.&#x000a0;Instill one drop of 2.5% topical phenylephrine to observe any vessel blanching and to distinguish between episcleritis versus scleritis.<xref ref-type="bibr" rid="article-28780.r2">[2]</xref></p>
      </sec>
      <sec id="article-28780.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Essential communication with internal medicine, eye care providers, and medical specialists (rheumatology) is required for proper medical management and to improve patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-28780.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28780&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28780">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/scleritis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28780">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28780/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28780">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28780.s17">
        <title>References</title>
        <ref id="article-28780.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okhravi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Odufuwa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McCluskey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lightman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Scleritis.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2005</year>
            <season>Jul-Aug</season>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>351</fpage>
            <page-range>351-63</page-range>
            <pub-id pub-id-type="pmid">15967190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28780.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniel Diaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sobol</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Gritz</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Treatment and management of scleral disorders.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>702</fpage>
            <page-range>702-717</page-range>
            <pub-id pub-id-type="pmid">27318032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28780.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Artifoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rothschild</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;zin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Ocular inflammatory diseases associated with rheumatoid arthritis.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>108</fpage>
            <page-range>108-16</page-range>
            <pub-id pub-id-type="pmid">24323074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28780.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sims</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Scleritis: presentations, disease associations and management.</article-title>
            <source>Postgrad Med J</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>88</volume>
            <issue>1046</issue>
            <fpage>713</fpage>
            <page-range>713-8</page-range>
            <pub-id pub-id-type="pmid">22977282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28780.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oray</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meese</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of non-infectious immune-mediated scleritis: current status and future prospects.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>827</fpage>
            <page-range>827-37</page-range>
            <pub-id pub-id-type="pmid">27055583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28780.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wieringa</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Wieringa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>ten Dam-van Loon</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Los</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Visual outcome, treatment results, and prognostic factors in patients with scleritis.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>379</fpage>
            <page-range>379-86</page-range>
            <pub-id pub-id-type="pmid">23177360</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
